Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Limited-Stage Small Cell Lung CancerTreatment of limited-stage small cell lung cancer may include the following:Combination chemotherapy and radiation therapy to the chest. Radiation therapy to the brain may later be given to patients with complete responses.Combination chemotherapy alone for patients who cannot be given radiation therapy.Surgery followed by chemotherapy.Surgery followed by chemotherapy and radiation therapy.Radiation therapy to the brain may be given to patients who have had a complete response, to prevent the spread of cancer to the brain.Clinical trials of new chemotherapy, surgery, and radiation treatments.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with
Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for NSCLC
In NSCLC, results of standard treatment are poor except for the most localized cancers. All newly diagnosed patients with NSCLC are potential candidates for studies evaluating new forms of treatment. Surgery is the most potentially curative therapeutic option for this disease. Postoperative chemotherapy may provide an additional benefit to patients with resected NSCLC. Radiation therapy combined with chemotherapy can produce a cure in a small number of patients and can provide palliation in most patients. Prophylactic cranial irradiation (PCI) may reduce the incidence of brain metastases, but there is no evidence of a survival benefit and the effect of PCI on quality of life is not known.[1,2] In patients with advanced-stage disease, chemotherapy or epidermal growth factor receptor (EGFR) kinase inhibitors offer modest improvements in median survival, though overall survival is poor.[3,4]Chemotherapy has produced short-term improvement in disease-related symptoms in patients with
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Small Cell Lung Cancer Treatment
Standard Treatment Options for Patients With Recurrent Small Cell Lung Cancer (SCLC)Standard treatment options for patients with recurrent SCLC include the following:Chemotherapy.Palliative therapy.At the time of recurrence, many SCLC patients are potential candidates for further therapy.ChemotherapyAlthough second-line chemotherapy has been shown to produce tumor regression, responses are usually short lived; the median survival is rarely more than 12 months and usually less than 6 months after second-line therapy. Response to first-line chemotherapy predicts for subsequent response to second-line therapy.As in other chemosensitive tumors (e.g., Hodgkin lymphoma and ovarian epithelial cancer), two main categories of patients receiving second-line chemotherapy have been described: sensitive and resistant. Sensitive patients have a first-line response that lasted more than 90 days after treatment was completed. These patients have the greatest benefit from second-line chemotherapy.
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (06 / 25 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Limited-Stage Small Cell Lung Cancer TreatmentAdded text as a list item to state that randomized trials have shown that doses higher than 25 Gy in 10 daily fractions do not improve long-term survival (cited Le Péchoux et al. and Wolfson et al. as references 32 and 33, respectively).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Lung Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?
Cancerprevention is action taken to lower the chance of getting cancer. By preventing cancer,the number of new cases of cancer in a group or population is lowered. Hopefully,this will lower the number of deaths caused by cancer. To prevent new cancers from starting,scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a ...
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Small Cell Lung Cancer
For more information from the National Cancer Institute about small cell lung cancer, see the following:Lung Cancer Home PageWhat You Need to Know About™ Lung CancerLung Cancer PreventionLung Cancer ScreeningDrugs Approved for Small Cell Lung CancerSmoking Home Page (Includes help with quitting)Cigarette Smoking: Health Risks and How to QuitSmoking in Cancer CareSecondhand Smoke and CancerFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Malignant Mesothelioma
Patients with stage I disease have a significantly better prognosis than those with more advanced stages. Because of the relative rarity of this disease, exact survival information based upon stage is limited.Definitions of TNMThe American Joint Committee on Cancer has designated staging by TNM classification to define malignant mesothelioma.International Mesothelioma Interest Group Staging System for Diffuse Malignant Pleural MesotheliomaTable 1. Primary Tumor (T)aa Reprinted with permission from AJCC: Pleural mesothelioma. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 271-7.TXPrimary tumor cannot be assessed.T0No evidence of primary tumor.T1Tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement.T1aNo involvement of the visceral pleura.T1bTumor also involving the visceral pleura.T2Tumor involving each of the ipsilateral
Lung Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityLung cancer has a tremendous impact on the health of the American public, with an estimated 228,190 new cases and 159,480 deaths predicted in 2013 in men and women combined. Lung cancer causes more deaths per year in the United States than the next four leading causes of cancer death combined. Lung cancer incidence and mortality rates increased markedly throughout most of the last century, first in men and then in women. The trends in lung cancer incidence and mortality rates have closely mirrored historical patterns of smoking prevalence, after accounting for an appropriate latency period. Because of historical differences in smoking prevalence between men and women, lung cancer rates in men have been consistently declining since 1990. The incidence rate in men declined from a high of 102.1 cases per 100,000 men in 1984 to 82.7 cases per 100,000 men in 2009. Consistent declines in women have not been seen.[1,2]
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Small Cell Lung Cancer
Before initiating treatment of a patient with small cell lung cancer (SCLC), an experienced lung cancer pathologist should review the pathologic material.Pathologic ClassificationThe current classification of subtypes of SCLC includes the following:Small cell carcinoma.Combined small cell carcinoma (i.e., SCLC combined with neoplastic squamous and/or glandular components).SCLC arising from neuroendocrine cells forms one extreme of the spectrum of neuroendocrine carcinomas of the lung.Neuroendocrine tumors include the following:Low-grade typical carcinoid.Intermediate-grade atypical carcinoid.High-grade neuroendocrine tumors including large-cell neuroendocrine carcinoma (LCNEC) and SCLC.Because of differences in clinical behavior, therapy, and epidemiology, these tumors are classified separately in the World Health Organization (WHO) revised classification. The variant form of SCLC called mixed small cell/large cell carcinoma was not retained in the revised WHO classification.